January 2015- Volume 11, Issue 1

January 2015

In this Issue

Preclinical

Going after vision loss with MANF

Going after vision loss with MANF

Amarantus announces positive preclinical data on effects of MANF on vision in model of retinitis pigmentosa

Better together?

Better together?

Combination cancer immunotherapy regimen shows promise for systemic immune response to cancer cells

Programmed hematopoietic cells show potential

Programmed hematopoietic cells show potential

Fate Therapeutics demonstrates treatment option that could be life-saver for people with hematologic malignancies

Getting the facts on FACT

Getting the facts on FACT

CBL0137 found to be effective in pancreatic cancer by targeting cancer stem cells

Research & Development

Preferred tox partner

Preferred tox partner

MicroMatrices enters partnership agreement for use of ACD’s RNAscope technology

Joint R&D on Accurins

Joint R&D on Accurins

BIND and Merck collaborate on developing nanomedicines for oncology, pipeline expansion

Focus on the microbiome

Focus on the microbiome

MIT partnership with Massachusetts General Hospital, other institutions to foster regional ecosystem for rapidly evolving field

Nanofiber vs. HIV

Nanofiber vs. HIV

Novel nanofiber-based technology developed at University of Missouri could help prevent HIV/AIDS transmission

Business & Government Policy

On the cutting edge

On the cutting edge

A roundup of instrumentation, software and other tools and technology news

MedImmune boosts cancer capacities with Definiens deal

MedImmune boosts cancer capacities with Definiens deal

Acquisition brings with it Tissue Phenomics, an imaging technology for biomarker identification

Pay to delay?

Pay to delay?

Ranbaxy and AstraZeneca win jury victory in test of what antitrust limits may be placed on reverse payment deals

Patent Docs: Copyright law threats to U.S. drug innovation

Patent Docs: Copyright law threats to U.S. drug innovation

The copyright case of Kirtsaeng v John Wiley & Sons decided by the U.S. Supreme Court last term could have far-reaching effects on the industry

Merck to pay $8.4 billion for Cubist

Merck to pay $8.4 billion for Cubist

Merck cites leadership in anti-infectives and identification of hospital acute care as a priority area

Discovery

Getting into the genetics of autism

Getting into the genetics of autism

Recent Nature study identifies 107 genes tied to autism risk

Blood plasma signature may be key to early autism diagnosis

Blood plasma signature may be key to early autism diagnosis

Test identified autistic children with 81-percent accuracy, according to Stemina-UC Davis report in PLOS One

AstraZeneca explores new target for heart disease

AstraZeneca explores new target for heart disease

Company will work with Lipigon on potential drugs to modulate lipoprotein lipase

Making medicines

Making medicines

GSK names winners of 2014 Discovery Fast Track Challenge and explains rationale for program

Two partners, three initiatives, five years

Two partners, three initiatives, five years

Evotec and Sanofi forge three-part deal to improve innovation in drug discovery and preclinical development

Diagnostics

A good attitude toward Longitude

A good attitude toward Longitude

CPA Global to support Longitude Prize 2014, which seeks to improve the antibiotic landscape

A harmonious transaction

A harmonious transaction

Roche acquires Ariosa Diagnostics, gains noninvasive Harmony Prenatal Test

Achieving good arthritis predictions

Achieving good arthritis predictions

New clinical data show Crescendo’s Vectra DA is a better predictor of joint damage in RA patients

myChoice CDx becomes TESARO’s choice

myChoice CDx becomes TESARO’s choice

TESARO directors select Myriad Genetics’ companion diagnostic for treating resistant ovarian cancer

Clinical Trials

Otsuka to acquire Avanir for $3.5 billion

Otsuka to acquire Avanir for $3.5 billion

Chemical entity AVP-786 for Alzheimer’s, soon to enter Phase 3 trials, is a major draw for Otsuka

On ‘cloud 9’ with new mobile health app

On ‘cloud 9’ with new mobile health app

Medidata, GSK evaluate impact of cloud-based tech on engagement, data quality and efficiencies in clinical trials

Nanomedicine platform shows mettle

Nanomedicine platform shows mettle

BIND presents positive Phase 2 results for nanomedicine platform in NSCLC at AACR annual symposium

Alion taps MPI for companion diagnostic

Alion taps MPI for companion diagnostic

Diagnostic would identify patients likely to respond to undisclosed ion channel inhibitor cancer treatment

Targeting MS at its root

Targeting MS at its root

Servier and GeNeuro to advance drug offering new approach to treating multiple sclerosis

Commentary

Guest commentary: Solutions to the drug development cycle and antibiotic resistance problems

Guest commentary: Solutions to the drug development cycle and antibiotic resistance problems

The cell-based assay arena has become highly prevalent due to the serious, major and mounting medical challenges facing healthcare internationally, and calorimetry provides the answers to a number of some of these critical challenges

Out of Order: Substance over volume

Out of Order: Substance over volume

For all of our improvements in throughput and other technological achievements, it is not clear that we've seen much improvement in the number or quality of drugs being produced, and we certainly haven’t made them less expensive. Maybe we need to ask some better questions about what we're doing, how we're doing it and why.

Q&A

Q&A: Taking a look at contracting and pricing

Q&A: Taking a look at contracting and pricing

A brief conversations with Lois Byra, vice president of contracting, strategy and compliance with Alliance Life Sciences Consulting Group

Feature

Show Preview: SLAS goes East

Show Preview: SLAS goes East

Washington, D.C., will host ‘what’s new in lab automation and screening’ for the SLAS2015 meeting

Editor's Focus

Making a big deal of mergers

Making a big deal of mergers

A lot of money is being spent to acquire pipelines and potential blockbusters, but it's happening at a time when the cost of development and commercialization is already through the roof.
Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue